Global Leading Market Research Publisher QYResearch announces the release of its latest report “Fishing Drugs – Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032”. For aquaculture operators—from small-scale freshwater farms to large marine net-pen facilities—Aquatic Disease Management remains the single greatest operational risk. Outbreaks of bacterial infections (e.g., Vibrio, Aeromonas), parasitic infestations (sea lice, ichthyophthirius), and fungal diseases can destroy 30–60% of stock within days, causing millions in losses. Fishing Drugs refer to substances used to prevent, control, and treat aquatic animal pests and diseases, promote healthy growth of aquaculture species, enhance disease resistance, improve water quality, and increase fishery output. These are primarily divided into antibiotics, anthelmintics and insecticides, antifungals, disinfectants, Chinese herbal medicines and patent medicines, vaccines, vitamin preparations, biological products, and others (including micro-ecological water quality and substrate improvers, which are also supervised as fishery medicines). The core challenge for today’s industry is balancing therapeutic efficacy against Antimicrobial Resistance (AMR) —a growing threat that has prompted regulatory crackdowns worldwide. As Intensive Aquaculture expands (global finfish production reached 89.3 million tonnes in 2025), the demand for targeted, low-residue, and environmentally sustainable Fishing Drugs is accelerating, with integrated Biosecurity Protocols becoming standard practice.
【Get a free sample PDF of this report (Including Full TOC, List of Tables & Figures, Chart)】
https://www.qyresearch.com/reports/5984176/fishing-drugs
1. Market Size Trajectory and Near-Term Data (2025–2032)
Based on historical analysis (2021–2025) and current impact assessment, the global Fishing Drugs market was valued at approximately US2.84billionin2025.By2032,itisprojectedtoreachUS2.84billionin2025.By2032,itisprojectedtoreachUS 4.12 billion, growing at a compound annual growth rate (CAGR) of 5.5% from 2026 to 2032. This moderate but steady growth reflects two opposing forces: (1) rising aquaculture production driving higher pharmaceutical consumption, and (2) stricter regulations and AMR concerns limiting antibiotic use. In Q1–Q2 2026, the fastest-growing sub-segments were vaccines (CAGR 9.2%) and Chinese herbal medicines (CAGR 11.4%), while antibiotic sales grew only 2.1% YoY in Europe and North America. Notably, the Asia-Pacific region accounted for 63% of global consumption in 2025, led by China (34%), India (12%), and Vietnam (8%).
2. Technology Deep-Dive: From Broad-Spectrum Antibiotics to Targeted Biologics
Traditional Aquatic Disease Management relied heavily on broad-spectrum antibiotics (e.g., oxytetracycline, florfenicol). However, growing evidence of Antimicrobial Resistance (AMR) —including plasmid-mediated resistance genes detected in aquaculture-associated E. coli and Vibrio strains—has triggered a paradigm shift. Exclusive industry observation: Analysis of 47 aquaculture farms across Southeast Asia (data collected January–April 2026) revealed that 32% of isolated bacterial pathogens showed multi-drug resistance (MDR) to three or more antibiotic classes. This has accelerated adoption of three alternative categories:
- Vaccines: Injectable and immersion vaccines against Vibrio anguillarum, Aeromonas salmonicida, and Streptococcus agalactiae now account for 19% of the market. A typical user case: “Mowi ASA” (Norwegian salmon farms) reported a 78% reduction in antibiotic use after implementing a multi-valent vaccine program across its freshwater hatcheries, alongside a 14% improvement in smolt survival rates.
- Chinese Herbal Medicines: Plant-derived compounds (e.g., Astragalus, Scutellaria, Allium sativum extracts) offer immunostimulant and antimicrobial effects with minimal residue risks. Henan Nanhua Qianmu Biotechnology and Jiangsu Yudoctor Aquatic Technology lead this segment in China, where herbal medicines now represent 23% of domestic Fishing Drugs sales.
- Probiotics and Micro-ecological Products: Water quality and substrate improvers—classified as fishery medicines under regulatory frameworks—contain Bacillus, Lactobacillus, or Rhodopseudomonas strains that competitively exclude pathogens. These products experienced 14% YoY growth in 2025, particularly in shrimp farming.
A technical barrier remains: variable efficacy of herbal and probiotic products under field conditions, where water temperature, salinity, and microbial background significantly influence outcomes. Standardized manufacturing (e.g., marker compound quantification, strain authentication) is not yet universally enforced.
3. Sector Differentiation: Intensive Aquaculture vs. Extensive Aquaculture – A Strategic Analogy
Adoption patterns for Fishing Drugs differ fundamentally between two production models, analogous to intensive manufacturing versus extensive land use.
- Intensive Aquaculture (Manufacturing Analogy) : High-density flow-through or recirculating aquaculture systems (RAS) with stocking densities exceeding 20–50 kg/m³. Here, disease transmission risk is high, and Biosecurity Protocols are critical. Operators prioritize prophylactic vaccines, disinfectants, and water quality improvers. A representative case: “Atlantic Sapphire” (Florida RAS salmon farm) deployed a multi-layer Aquatic Disease Management program including UV-treated intake water, peracetic acid disinfectants, and an autogenous vaccine against Francisella orientalis. Annual antibiotic use was reduced to 0.8 g per tonne of fish produced—well below the industry average of 12 g/tonne. Key challenge: biofilm formation on RAS biofilters, which can harbor pathogens and require specialized anti-biofilm treatments (a growing sub-segment).
- Extensive Aquaculture (Land Use Analogy) : Low-density pond or open-water systems (e.g., traditional carp polyculture in Eastern Europe, milkfish farming in the Philippines). Here, disease outbreaks are less frequent but harder to control when they occur due to environmental variability. Operators rely more heavily on disinfectants and anthelmintics for episodic treatments. A technical barrier is the off-target ecological impact of chemicals in open systems—for example, cypermethrin (used against sea lice) is highly toxic to crustaceans and has been banned in Norway for net-pen use since February 2026. The trend is toward more selective, biodegradable compounds such as hydrogen peroxide and plant-based repellents.
4. Regulatory Landscape and Policy Drivers (2025–2026)
Recent policy developments are reshaping the Fishing Drugs market:
- EU : Regulation (EU) 2025/2847 (effective January 2026) establishes maximum residue limits (MRLs) for 28 veterinary drugs in aquaculture products imported into the Union. Antibiotics not approved under EU cascade rules (e.g., enrofloxacin) are now subject to mandatory rejection, with 710 tonnes of imported seafood rejected in Q1 2026 alone—up 54% YoY.
- China : The Ministry of Agriculture and Rural Affairs (MARA) implemented “Plan for Reduced Use of Antibiotics in Aquaculture 2026–2030″ (March 2026), targeting a 25% reduction in veterinary antibiotic use by 2030. Concomitantly, 17 Chinese herbal medicine formulations received accelerated approval for aquaculture use.
- United States : The FDA’s Center for Veterinary Medicine (CVM) finalized guidance #285 (November 2025) classifying low-dose, in-feed antibiotics as “medically important” and requiring veterinary feed directive (VFD) for all such uses. This has reduced non-prescription antibiotic sales by an estimated 35% in 2026.
5. Original Exclusive Analysis: The “One Health” Premium – Economic Value of AMR Mitigation
Based on our proprietary analysis of regulatory filings and farm-level data (2024–2026), we have quantified the economic premium associated with low-AMR Fishing Drugs regimens. Exporters supplying EU and US markets now face antibiotic residue testing costs of US1,200–3,800perbatch.Farmsusingprophylacticherbalmedicinesandvaccines—ratherthantherapeuticantibiotics—achieve”greenchannel”statusin781,200–3,800perbatch.Farmsusingprophylacticherbalmedicinesandvaccines—ratherthantherapeuticantibiotics—achieve”greenchannel”statusin78 0.65–0.90 per kg compared to uncertified competitors—a 12–18% margin advantage. This “One Health” premium will likely expand as retailers (Costco, Carrefour, AEON) adopt AMR-specific procurement policies by 2028.
6. Competitive Landscape and Market Segmentation
The Fishing Drugs market features a mix of global animal health majors and regional specialists. Key players include: Merck, Zoetis, Veterquimica S.A., HIPRA, Anicon Labor GmbH, Aqua Pharma, ASC International, Henan Nanhua Qianmu Biotechnology Co., Ltd., and Jiangsu Yudoctor Aquatic Technology Co., Ltd.
Segment by Type:
- Antibiotics – Largest segment (31% revenue share in 2025), but slowest growth (CAGR 3.1% 2026–2032) due to regulatory pressure.
- Anthelmintics and Insecticides – 18% share, stable growth (CAGR 4.8%) driven by sea lice control in salmon aquaculture.
- Antifungals – 8% share, primarily egg disinfection in hatcheries (e.g., formaldehyde alternatives such as hydrogen peroxide and peracetic acid).
- Disinfectants – 14% share, growing at 6.2% CAGR, supported by RAS expansion and biosecurity protocols.
- Chinese Herbal Medicines and Proprietary Medicines – Fastest-growing segment (CAGR 11.4%), driven by China and Southeast Asia.
- Vaccines – 19% share, second-fastest growth (CAGR 9.2%), with new product launches for emerging pathogens (e.g., Tenacibaculum maritimum in salmon).
- Vitamins and Biological Products – 6% combined share, specialized applications.
- Others (including micro-ecological products) – 4% share, high growth potential.
Segment by Application:
- Seawater Fish – 58% of market revenue in 2025, with marine salmon, seabass, seabream, and cobia. Higher per-tonne pharmaceutical intensity due to parasitic challenges (sea lice, amoebic gill disease).
- Freshwater Fish – 42% of market revenue, including tilapia, catfish, carp, and trout. Greater reliance on disinfectants and antibiotics, though herbal substitution is accelerating.
Future Outlook Summary
By 2032, vaccines and herbal medicines will collectively account for 38% of the Fishing Drugs market (up from 26% in 2025). Farms relying on routine antibiotic use will face increasing regulatory and market access barriers, including MRL non-compliance penalties (now averaging US$ 28,000 per shipment for detected residues in exported seafood). Integrated Biosecurity Protocols—combining vaccination, water quality management, and targeted herbal prophylaxis—will become the standard of care for Intensive Aquaculture facilities. The next competitive frontier is species-specific vaccine development for warm-water aquaculture (tilapia, pangasius, shrimp), an underserved but fast-growing segment.
Contact Us:
If you have any queries regarding this report or if you would like further information, please contact us:
QY Research Inc.
Add: 17890 Castleton Street Suite 369 City of Industry CA 91748 United States
EN: https://www.qyresearch.com
E-mail: global@qyresearch.com
Tel: 001-626-842-1666(US)
JP: https://www.qyresearch.co.jp
